When to start antiretroviral therapy

Current HIV/AIDS Reports

Volumn 3, Issue 2, 2006, Pages 66-73

  Wang, Cunlin ^a   Masho, Saba W ^b   Nixon, Daniel E ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

DRUG RESISTANCE; DRUG USE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; REVIEW; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; HEPATITIS C; HIV INFECTIONS; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL LOAD;

EID: 33750325254     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-006-0020-3     Document Type: Review

References (67)

1. Ezzell C: AZT given the green light for clinical treatment of AIDS. Nature 1987, 326:430.
2. Ho DD: Time to hit HIV, early and hard. N Engl J Med 1995, 333:450-451.
3. Adult HIV treatment guidelines updated. AIDS Treat News 2005, 411:5.
4. Lalezari JP, Henry K, O'Hearn M, et al.: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003, 348:2175-2185.
5. Harrington M: Ten years of HAART. Res Initial Treat Action 2005, 11:28-38.
6. Gallant IH, DeJesus E, Arribas JR, et al.: Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006, 354:251-260. Superior response from once-daily tenofovir, emtricitabine, and efavirenza on immunologic, virologic, and adverse events.
7. Macalino GE, Mitty IA, Bazerman EB, et al.: Modified directly observed therapy for the treatment of HIV-seropositive substance users: lessons learned from a pilot study. Clin Infect Dis 2004, 38(Suppl 5):S393-S397.
8. Mitty JA, Macalino GE, Bazerman LB, et al.: The use of community-based modified directly observed therapy for the treatment of HIV-infected persons. J Acquir Immune Defic Syndr 2005, 39:545-550. Community-based DOT is feasible and effective among populations with history of treatment failure and drug abuse.
9. Pilcher CD, Eron JI Jr, Galvin S, et al.: Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest 2004, 113:937-945.
10. Strain MC, Little SJ, Daar ES, et al.: Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005, 191:1410-1418. Receiving HAART during primary HIV infection can both reduce the size and increase the decay rate of viral reservoir.
11. Smith DE, Walker BD, Cooper DA, et al.: Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS 2004, 18:709-718.
12. Castilla J, Del Romero J, Hernando V, et al.: Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005, 40:96-101. Analysis of 393 HIV discordant couples showed that HAART may account for 80% reduction of HIV heterosexual transmission.
13. Celum CL, Robinson NI, Cohen MS: Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection. J Infect Dis 2005, 191(Suppl 1):S107-S114.
14. Opravil M, Ledergerber B, Furrer H, et al.: Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 10(6)/L. AIDS 2002, 16:1371-1381. Three-year follow-up of 283 pairs of treated versus nontreated patients with baseline CD4 count of 350/μL showed HAART was associated with four- to fivefold reduction on clinical progression.
15. Palella Ff Jr, Deloria-Knoll M, Chmiel JS, et al.: Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003, 138:620-626.
16. 3. J Infect Dis 2005, 192:950-957.
17. Mauskopf J, Kitahata M, Kauf T, et al.: HIV antiretroviral treatment: early versus later. J Aquir Immune Defic Syndr 2005, 39:562-569.
18. Dragsted UB, Mocroft A, Vella S, et al.: Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. J Infect Dis 2004, 190:148-155.
19. Egger M, May M, Chene G, et al.: Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119-129. Analysis from 12,574 patients showed that response of HAART at CD4 200/μL or more or VL 100,000 copies/mL or less was superior to that of at CD4 less than 200/uL or VL greater than 100,000 copies/mL.
20. Hogg RS, Yip B, Chan KJ, et al.: Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001, 286:2568-2577.
21. Cozzi LA, Phillips AN, D'Arminio MA, et al.: When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. AIDS 2001, 15:983-990.
22. Phillips AN, Staszewski S, Weber R, et al.: HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001, 286:2560-2567.
23. Cole SR, Li R, Anastos K, et al.: Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies. Stat Med 2004, 23:3351-3363. Simulation study using multi-imputation to account for lead-time bias.
24. Prins M, Hernandez Aguado I, Brettle RP, et al.: Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Sero-converter Study among injecting drug users. AIDS 1997, 11:1747-1756.
25. Prins M, Sabin CA, Lee CA, et al.: Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men. AIDS 2000, 14:1829-1837.
26. van Asten L, Zangerle R, Hernandez Aguado I, et al.: Do HIV disease progression and HAART response vary among injecting drug users in Europe? Eur J Epidemiol 2005, 20:795-804.
27. Wang C, Vlahov D, Galai N, et al.: Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis 2004, 190:1046-1054. Survival approximated to HIV seronegative IDUs only when receiving HAART at CD4 greater than 350/μL.
28. Jensen-Fangel S, Pedersen L, Pedersen C, et al.: Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS 2004, 18:89-97.
29. Paredes R, Mocroft A, Kirk O, et al.: Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000, 160:1123-1132.
30. Le Moing V, Chene G, Carrieri MP, et al.: Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002, 16:21-29.
31. O'Brien ME, Clark RA, Besch CL, et al: Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003, 34:407-414.
32. Piroth L, Binquet C, Buisson M, et al.: Clinical, immunological and virological evolution in patients with CD4 T-cell count above 500/mm3: is there a benefit to treat with highly active antiretroviral therapy (HAART)? Eur J Epidemiol 2004, 19:597-604.
33. Lange CG, Valdez H, Medvik K, et al.: CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol 2002, 102:154-161.
34. D'Amico R, Yang Y, Mildvan D, et al.: Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067. J Clin Immunol 2005, 25:106-115.
35. Lange CG, Lederman MM, Medvik K, et al.: Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003, 17:2015-2023.
36. Levy JA: Effect of HIV on various tissues and organ systems in the host. In HIV and the Pathogenesis of AIDS. Washington, DC: American Society for Microbiology Press; 1998:189-228.
37. Phillips AN, Lepri AC, Lampe F, et al.: When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS 2003, 17:1863-1869.
38. Kaufmann GR, Zaunders JJ, Cunningham P, et al.: Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. AIDS 2000, 14:2643-2651.
39. Rosenberg ES, Altfeld M, Poon SH, et al.: Immune control of HIV-1 after early treatment of acute infection. Nature 2000, 407:523-526.
40. Yerly S, Kaiser L, Perneger TV, et al.: Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. AIDS 2000, 14:243-249. With a more sensitive test (< 3 copies/mL), treatment at primary infection or CD4 count greater than 500/μL showed more complete viral suppression.
41. Pires A, Hardy G, Gazzard B, et al.: Initiation of antiretroviral therapy during recent HIV-1 infection results in lower residual viral reservoirs. J Acquir Immune Defic Syndr 2004, 36:783-790.
42. Vernazza PL: Genital shedding of HIV-1 despite successful antiretroviral therapy. Lancet 2001, 358:1564.
43. Porco TC, Martin JN, Page-Shafer KA, et al.: Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004, 18:81-88.
44. Deeks SG: Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003, 362:2002-2011.
45. Ribera E, Rodriguez-Pardo D, Rubio M, et al.: Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients. Antivir Ther 2005, 10:605-614.
46. Maggiolo F, Migliorino M, Maserati R, et al.: Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir Ther 2001, 6:249-253.
47. Duval X, Journot V, Leport C, et al.: Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy. Clin Infect Dis 2004, 39:248-255.
48. Maggiolo F, Ripamonti D, Gregis G, et al.: Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS 2004, 18:439-446.
49. Antinori A, Cingolani A, Perno CF: Structured treatment interruption in HIV-infected patients failing on multidrug therapy: is there a future for this strategy? AIDS 2005, 19:1691-1694.
50. Ghosn J, Wirden M, Ktorza N, et al: No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. AIDS 2005, 19:1643-1647.
51. Lawrence J, Mayers DL, Hullsiek KH, et al.: Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003, 349:837-846.
52. + cells < 250/μL, and stopped when counts rose over 350/μL) was detrimental in clinical progression and occurrence of therapy-associated complications, compared with continuous therapy.
53. Ananworanich J, Siangphoe U, Hill A, et al.: Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study. J Acquir Immune Defic Syndr 2005, 39:523-529.
54. Pellegrin I, Thiebaut R, Blanco P, et al.: Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/ microl? Impact on immunovirological parameters. J Med Virol 2005, 77:164-172. Nadir CD4 at HAART initiation predicted the outcome of STIs.
55. Fernandez Guerrero ML, Rivas P, Molina M, et al.: Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy. Clin Infect Dis 2005, 41:390-394.
56. Centers for Disease Control and Prevention: Drug-associated HIV transmission continues in the United States. http://www.cdc.gov/hiv/pubs/facts/ idu.htm. Accessed February 6, 2006.
57. Sabine C: AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? AIDS 2005, 19:1995-2000.
58. Qurishi N, Kreuzberg C, Luchters G, et al.: Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003, 362:1708-1713.
59. Miller MF, Haley C, Koziel MJ, Rowley CF: Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis 2005, 41:713-720.
60. Rockstroh JK, Mocroft A, Soriano V, et al.: Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005, 192:992-1002.
61. Soriano V, Sulkowski M, Bergin C, et al.: Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002, 16:813-828.
62. Braitstein P, Palepu A, Dieterich D, et al.: Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C. AIDS 2004, 18:2221-2234.
63. Tural C, Fuster D, Tor J, et al.: Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat 2003, 10:118-125.
64. Vento S, Garofano T, Renzini C, et al.: Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS 1998, 12:116-117.
65. Mehta SH, Thomas DL, Torbenson M, et al.: The effect of anti-retroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 2005, 41:123-131.
66. Sterling TR, Chaisson RE, Moore RD: HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001, 15:2251-2257.
67. Anastos K, Barron Y, Miotti P, et al.: Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease. Arch Intern Med 2002, 162:1973-1980.